Legend Biotech Corporation (NasdaqGS: LEGN)
Health Care · Biotechnology · US
$21.82
+2.63% today · -38.6% 1Y
Legend Biotech Corporation (NasdaqGS: LEGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.23B and employs 3,100 people.
Over the last twelve months the share price has lost 38.6%, trading between 16.24 and 37.50.
Tweenvest scores Legend Biotech Corporation across four factors: quality 41/100, value 65/100, growth 100/100. Its strongest factor is growth.
LEGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.23B
- Revenue (TTM)
- $1.27B
- P/E
- —
- EPS
- -0.50
- Dividend yield
- —
- Beta (5Y)
- 0.39
- 52-week high
- $37.50
- 52-week low
- $16.24
- Avg volume (3M)
- —
- Shares outstanding
- 193.77M
- Employees
- 3,100
- Next earnings
- —
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
- Founded
- 2014
- Listed since
- Jun 5, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.